New Use of Preoperative Fibrinogen in Ovarian Cancer Management

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2023 Dec 22

PMID 38130314

Authors

Jiacong Wu

Ya Zhang

Guangquan Liu

Lili Ge

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC) is often diagnosed at an advanced stage due to the absence of specific symptoms in its early stages. And the prognosis greatly depends on when the disease is diagnosed. Thus, we conducted to evaluate the value of preoperative fibrinogen (Fib) levels for the diagnosis of OC in the hope of improving its diagnostic efficiency.

Methods: A total of 126 ovarian tumor patients were retrospectively included in this study. Four candidate OC markers, including cancer antigen 125 (CA125), Fib, platelet (PLT) and homocysteine (Hcy) were employed to establish a diagnosis model for OC. The diagnostic performance of the model was evaluated using the area under the receiver operating characteristic curve (AUC) and Youden index.

Results: All included markers could be used for the diagnosis of OC. The AUCs of CA125, Fib, PLT and Hcy were 0.881, 0.825, 0.676 and 0.647, respectively. The new diagnosis model combining CA125 and Fib (CA125-Fib) had a higher AUC (0.924), Youden index (0.730), and best sensitivity (SN) (74.6%) and specificity (SP) (98.41%). CA125-Fib also had a high value in the diagnosis of stage I-II OC (AUC, Youden index, SN and SP: 0.853, 0.624, 81.48% and 80.95%).

Conclusions: Fib could be used for OC diagnosis. In particular, the combination of Fib and CA125 could further improve the diagnostic efficiency. And the diagnostic value of PLT and Hcy was found to be poor.

Citing Articles

A new risk algorithm combining D-dimer and HE4 differentiates borderline tumor from patients with ovarian tumor.

Zhang M, Zhang Y, Liu G, Ge L Transl Cancer Res. 2025; 14(1):93-101.

PMID: 39974418 PMC: 11833360. DOI: 10.21037/tcr-24-1276.

References

Previs R, Secord A . Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. Obstet Gynecol Clin North Am. 2019; 46(1):67-88. DOI: 10.1016/j.ogc.2018.09.005. View

Franzese E, Centonze S, Diana A, Carlino F, Guerrera L, Di Napoli M . PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2018; 73:1-9. DOI: 10.1016/j.ctrv.2018.12.002. View

Abdulrahman G, Das N, Lutchman Singh K . The predictive role of thrombocytosis in benign, borderline and malignant ovarian tumors. Platelets. 2019; 31(6):795-800. DOI: 10.1080/09537104.2019.1686755. View

Corbaux P, You B, Glasspool R, Yanaihara N, Tinker A, Lindemann K . Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. Eur J Cancer. 2023; 191:112966. DOI: 10.1016/j.ejca.2023.112966. View

Yang J, Ma J, Cheng S, Wang Y . The Combination of Plasma Fibrinogen Concentration and Neutrophil Lymphocyte Ratio (F-NLR) as a Prognostic Factor of Epithelial Ovarian Cancer. Onco Targets Ther. 2020; 13:7283-7293. PMC: 7429409. DOI: 10.2147/OTT.S264118. View

Li Y, Yang J, Cheng S, Wang Y . Prognostic significance of FA score based on plasma fibrinogen and serum albumin in patients with epithelial ovarian cancer. Cancer Manag Res. 2019; 11:7697-7705. PMC: 6698597. DOI: 10.2147/CMAR.S211524. View

Li J, Wang R . Prediction of the survival of patients with advanced-stage ovarian cancer patients undergoing interval cytoreduction with the use of computed tomography reevaluation after neoadjuvant chemotherapy. J Obstet Gynaecol Res. 2023; 49(11):2700-2710. DOI: 10.1111/jog.15760. View

Bukhari S, Zafar K, Rajoka M, Ibrahim Z, Javed S, Sadiq R . Oxidative stress-induced DNA damage and homocysteine accumulation may beinvolved in ovarian cancer progression in both young and old patients. Turk J Med Sci. 2016; 46(3):583-9. DOI: 10.3906/sag-1406-17. View

Stone R, Nick A, McNeish I, Balkwill F, Han H, Bottsford-Miller J . Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366(7):610-8. PMC: 3296780. DOI: 10.1056/NEJMoa1110352. View

10.

Sartor H, Bjurberg M, Asp M, Kahn A, Brandstedt J, Kannisto P . Imaging ovarian cancer - from baseline characteristics to high-risk image factors. J Ovarian Res. 2023; 16(1):78. PMC: 10108495. DOI: 10.1186/s13048-023-01154-w. View

11.

Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T . HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian.... Int J Cancer. 2014; 136(3):699-708. DOI: 10.1002/ijc.29011. View

12.

Mimoun C, Benifla J, Fauconnier A, Huchon C . Intraoperative Clinical Examination for Assessing Pelvic and Para-Aortic Lymph Node Involvement in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2020; 9(9). PMC: 7564081. DOI: 10.3390/jcm9092793. View

13.

Dewan R, Dewan A, Jindal M, Bhardawaj M . Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses. Asian Pac J Cancer Prev. 2019; 20(4):1103-1108. PMC: 6948914. DOI: 10.31557/APJCP.2019.20.4.1103. View

14.

Jiang C, Li Y, Li Y, Liu L, Wang X, Wu W . Fibrinogen promotes gallbladder cancer cell metastasis and extravasation by inducing ICAM1 expression. Med Oncol. 2022; 40(1):10. DOI: 10.1007/s12032-022-01874-x. View

15.

Kim J, Park E, Kim O, Schilder J, Coffey D, Cho C . Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2018; 10(11). PMC: 6267333. DOI: 10.3390/cancers10110433. View

16.

Cao Y, Ni X, Wang Y, Wang L, Yuan K, Gan G . Clinical and prognostic significance of combined plasma fibrinogen concentrations and the monocyte-to-lymphocyte ratio in patients with ovarian cancer. Ann Transl Med. 2019; 7(11):242. PMC: 6603346. DOI: 10.21037/atm.2019.04.78. View

17.

Guo B, Lian W, Liu S, Cao Y, Liu J . Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer. Oncol Lett. 2019; 17(6):5523-5528. PMC: 6507457. DOI: 10.3892/ol.2019.10264. View

18.

Huang K, Xu S, Wang J, Ge L, Xu J, Jia X . Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors. J Ovarian Res. 2023; 16(1):37. PMC: 9912622. DOI: 10.1186/s13048-023-01106-4. View

19.

Saadeh N, Alfaqih M, Mansour H, Khader Y, Saadeh R, Al-Dwairi A . Serum homocysteine is associated with polycystic ovarian syndrome in Jordan. Biomed Rep. 2018; 9(5):439-445. PMC: 6200971. DOI: 10.3892/br.2018.1149. View

20.

Martinez-Camblor P, Pardo-Fernandez J . The Youden Index in the Generalized Receiver Operating Characteristic Curve Context. Int J Biostat. 2019; 15(1). DOI: 10.1515/ijb-2018-0060. View